万赛维使用说明

It is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

Induction therapy for CMV retinitis

For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity.

Maintenance treatment of CMV retinitis

After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

Prevention of CMV infection in transplant patients

For kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Medication for elderly patients:

Safety and efficacy studies have not been conducted in older adults.

Pediatric Use: Safety and efficacy studies have not been conducted in children. Because the pharmacokinetics of valganciclovir hydrochloride tablets have not been studied in children, its use in children is not recommended.

Medication for pregnant women:

Due to the rapid and substantial conversion of valganciclovir to ganciclovir, reproductive toxicity studies have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects.

It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment.

There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus.

The developmental effects of valganciclovir or cyclovir on perinatal and postnatal infants have not been studied, but it must be considered that ganciclovir may be excreted in breast milk and cause serious adverse reactions in infants. Therefore, when considering the possible benefits of valganciclovir hydrochloride tablets to nursing mothers, a decision should be made to discontinue medication or discontinue breastfeeding.

Tablets must not be broken or crushed. Due to the potential teratogenic and carcinogenic effects in humans, extreme caution should be used when handling broken tablets. Avoid direct contact with skin or mucous membranes with broken or crushed tablets. If this occurs, flush skin thoroughly with soap and water and eyes with plenty of water.